Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29906797 | 1.00 | KDM4E (0.60) | KDM4EMAPTALDH1A1ACHECRBN | |
| SCHEMBL28229042 | 0.93 | KDM4E (0.71) | KDM4EMAPTALDH1A1ACHECRBN | |
| SCHEMBL2730135 | 0.89 | KDM4E (0.76) | KDM4EMAPTALDH1A1ACHEGFER | |
| SCHEMBL29365830 | 0.89 | KDM4E (0.76) | KDM4EMAPTALDH1A1ACHEGFER | |
| SCHEMBL28212622 | 0.85 | NNMT (0.50) | KDM4EMAPTACHECRBNGFER | |
| SCHEMBL2638095 | 0.85 | KDM4E (0.81) | KDM4EMAPTALDH1A1ACHECRBN | |
| SCHEMBL29530477 | 0.85 | KDM4E (0.81) | KDM4EMAPTALDH1A1ACHECRBN | |
| Hydrochloric Acid SCHEMBL698487 | 0.84 | KDM4E (0.78) | KDM4EMAPTALDH1A1ACHECRBN | |
| SCHEMBL11808846 | 0.84 | MAPT (0.50) | KDM4EMAPTALDH1A1ACHECRBN | |
| SCHEMBL27950742 | 0.81 | CRBN (0.43) | KDM4EMAPTALDH1A1ACHECRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | claimed |
| EP-2817310-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4]TRIAZOLO [1, 5 -A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | claimed |
| WO-2013124026-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | claimed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025036269-A1 | COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF | 青岛普泰科生物医药科技有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2025008060-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| CN-108276382-B | Cyclin-dependent kinase inhibitor and application thereof | 南京圣和药物研发有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110357876-B | Azabicyclooctane derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| WO-2010017827-A1 | 6-SUBSTITUTED 1-SULFONYL-2, 3-DIHYDRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2010-02-18 | — | — | WO | disclosed |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-07-02 | — | — | US | disclosed |
| CN-101263116-A | Novel heterobicyclic derivatives useful as liver carnitine palmitoyl transferase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| CN-101056632-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-10-17 | — | — | CN | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | KDM4E 2575/4885MAPT 1807/4885ALDH1A1 170/4885 |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | KDM4E 4265/4885MAPT 641/4885ALDH1A1 1285/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | KDM4E 2541/4885MAPT 301/4885ALDH1A1 1493/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | KDM4E 2541/4885MAPT 301/4885ALDH1A1 1493/4885 |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | SYK, EIF2AK4, BTK | KDM4E 1884/4885MAPT 4614/4885ALDH1A1 4830/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | KDM4E 2541/4885MAPT 301/4885ALDH1A1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.